A citation-based method for searching scientific literature

Kiyoshi Yoshino, Takayuki Enomoto, Masami Fujita, Yutaka Ueda, Toshihiro Kimura, Eiji Kobayashi, Tateki Tsutsui, Tadashi Kimura. Int J Clin Oncol 2013
Times Cited: 19







List of co-cited articles
165 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
David R Crotzer, Charlotte C Sun, Robert L Coleman, Judith K Wolf, Charles F Levenback, David M Gershenson. Gynecol Oncol 2007
104
68

Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
M Takano, T Sugiyama, N Yaegashi, M Sakuma, M Suzuki, Y Saga, K Kuzuya, J Kigawa, M Shimada, H Tsuda,[...]. Int J Gynecol Cancer 2008
55
42

Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma.
Hiroaki Kajiyama, Kiyosumi Shibata, Mika Mizuno, Eiko Yamamoto, Sawako Fujiwara, Tomokazu Umezu, Shiro Suzuki, Toru Nakanishi, Tetsuro Nagasaka, Fumitaka Kikkawa. Int J Gynecol Cancer 2012
26
42

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.
Aikou Okamoto, Rosalind M Glasspool, Seiji Mabuchi, Noriomi Matsumura, Hiroyuki Nomura, Hiroaki Itamochi, Masashi Takano, Tadao Takano, Nobuyuki Susumu, Daisuke Aoki,[...]. Int J Gynecol Cancer 2014
77
31

Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
Satoshi Takakura, Masashi Takano, Fumiaki Takahashi, Toshiaki Saito, Daisuke Aoki, Noriyuki Inaba, Kiichiro Noda, Toru Sugiyama, Kazunori Ochiai. Int J Gynecol Cancer 2010
47
26


Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases.
Masashi Takano, Yoshihiro Kikuchi, Kazuya Kudoh, Tomoko Goto, Kenichi Furuya, Ryoko Kikuchi, Tsunekazu Kita, Keiichi Fujiwara, Tanri Shiozawa, Daisuke Aoki. Int J Clin Oncol 2011
34
26

Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
Chih-Ming Ho, Yun-Ju Huang, Tze-Chien Chen, Shih-Hung Huang, Fu-Shing Liu, Chan-Chao Chang Chien, Mu-Hsien Yu, Tsui-Lien Mao, Tao-Yeuan Wang, Chang-Yao Hsieh. Gynecol Oncol 2004
82
26

Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
John K Chan, Deanna Teoh, Jessica M Hu, Jacob Y Shin, Kathryn Osann, Daniel S Kapp. Gynecol Oncol 2008
272
26

Clear cell carcinoma of the ovary: a review of the literature.
Marcela G del Carmen, Michael Birrer, John O Schorge. Gynecol Oncol 2012
152
26

ARID1A mutations in endometriosis-associated ovarian carcinomas.
Kimberly C Wiegand, Sohrab P Shah, Osama M Al-Agha, Yongjun Zhao, Kane Tse, Thomas Zeng, Janine Senz, Melissa K McConechy, Michael S Anglesio, Steve E Kalloger,[...]. N Engl J Med 2010
26

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
662
26

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
M K B Parmar, J A Ledermann, N Colombo, A du Bois, J-F Delaloye, G B Kristensen, S Wheeler, A M Swart, W Qian, V Torri,[...]. Lancet 2003
812
21

A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge.
Gabriella Ferrandina, Francesco Legge, Valentina Mey, Sara Nannizzi, Simona Ricciardi, Marco Petrillo, Giacomo Corrado, Giovanni Scambia. Cancer Chemother Pharmacol 2007
9
44

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease.
B A Goff, R Sainz de la Cuesta, H G Muntz, D Fleischhacker, M Ek, L W Rice, N Nikrui, H K Tamimi, J M Cain, B E Greer,[...]. Gynecol Oncol 1996
273
21

Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010.
Michael S Anglesio, Mark S Carey, Martin Köbel, Helen Mackay, David G Huntsman. Gynecol Oncol 2011
175
21

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
John K Chan, William Brady, Bradley J Monk, Jubilee Brown, Mark S Shahin, Peter G Rose, Jae-Hoon Kim, Angeles Alvarez Secord, Joan L Walker, David M Gershenson. Gynecol Oncol 2018
31
21

Differences in tumor type in low-stage versus high-stage ovarian carcinomas.
Martin Köbel, Steve E Kalloger, David G Huntsman, Jennifer L Santos, Kenneth D Swenerton, Jeffrey D Seidman, C Blake Gilks. Int J Gynecol Pathol 2010
235
21

Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
Hideaki Ogiwara, Kazuaki Takahashi, Mariko Sasaki, Takafumi Kuroda, Hiroshi Yoshida, Reiko Watanabe, Ami Maruyama, Hideki Makinoshima, Fumiko Chiwaki, Hiroki Sasaki,[...]. Cancer Cell 2019
98
21

Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Toru Sugiyama, Aikou Okamoto, Takayuki Enomoto, Tetsutaro Hamano, Eriko Aotani, Yasuhisa Terao, Nao Suzuki, Mikio Mikami, Nobuo Yaegashi, Kiyoko Kato,[...]. J Clin Oncol 2016
76
21

ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Benjamin G Bitler, Shuai Wu, Pyoung Hwa Park, Yang Hai, Katherine M Aird, Yemin Wang, Yali Zhai, Andrew V Kossenkov, Ana Vara-Ailor, Frank J Rauscher,[...]. Nat Cell Biol 2017
115
21

Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Ronald L Chandler, Jeffrey S Damrauer, Jesse R Raab, Jonathan C Schisler, Matthew D Wilkerson, John P Didion, Joshua Starmer, Daniel Serber, Della Yee, Jessie Xiong,[...]. Nat Commun 2015
174
21

Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Takafumi Kuroda, Hideaki Ogiwara, Mariko Sasaki, Kazuaki Takahashi, Hiroshi Yoshida, Takako Kiyokawa, Kazuki Sudo, Kenji Tamura, Tomoyasu Kato, Aikou Okamoto,[...]. Gynecol Oncol 2019
15
26

Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
Hiroaki Itamochi, Tetsuro Oishi, Nao Oumi, Satoshi Takeuchi, Kosuke Yoshihara, Mikio Mikami, Nobuo Yaegashi, Yasuhisa Terao, Kazuhiro Takehara, Kimio Ushijima,[...]. Br J Cancer 2017
41
21

Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.
Seiji Mabuchi, Toru Sugiyama, Tadashi Kimura. J Gynecol Oncol 2016
65
21

A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.
Stephanie Lheureux, Anna Tinker, Blaise Clarke, Prafull Ghatage, Stephen Welch, Johanne I Weberpals, Neesha C Dhani, Marcus O Butler, Katia Tonkin, Qian Tan,[...]. Clin Cancer Res 2018
28
21

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011
15

Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer.
T Sugiyama, M Yakushiji, T Nishida, K Ushijima, N Okura, J Kigawa, N Terakawa. Cancer Lett 1998
54
15

Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial.
H Utsunomiya, J Akahira, S Tanno, T Moriya, M Toyoshima, H Niikura, K Ito, Y Morimura, Y Watanabe, N Yaegashi. Int J Gynecol Cancer 2006
49
15

Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
J Al-Barrak, J L Santos, A Tinker, P Hoskins, C B Gilks, H Lau, K D Swenerton. Gynecol Oncol 2011
17
17

Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: is it possible?
Hiroaki Kajiyama, Kiyosumi Shibata, Mika Mizuno, Satoyo Hosono, Michiyasu Kawai, Tetsuro Nagasaka, Fumitaka Kikkawa. Hum Reprod 2011
41
15

Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.
Donald R Schwartz, Sharon L R Kardia, Kerby A Shedden, Rork Kuick, George Michailidis, Jeremy M G Taylor, David E Misek, Rong Wu, Yali Zhai, Danielle M Darrah,[...]. Cancer Res 2002
339
15

Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study.
Francescapaola Magazzino, Dionyssios Katsaros, Alessandro Ottaiano, Angiolo Gadducci, Carmela Pisano, Roberto Sorio, Emanuela Rabaiotti, Giovanni Scambia, Gennaro Cormio, Luca Scarampi,[...]. Int J Gynecol Cancer 2011
28
15

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
Seiji Mabuchi, Chiaki Kawase, Deborah A Altomare, Kenichirou Morishige, Kenjiro Sawada, Masami Hayashi, Masahiko Tsujimoto, Mareo Yamoto, Andres J Klein-Szanto, Russell J Schilder,[...]. Clin Cancer Res 2009
119
15

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.
M Takano, Y Kikuchi, N Yaegashi, K Kuzuya, M Ueki, H Tsuda, M Suzuki, J Kigawa, S Takeuchi, H Tsuda,[...]. Br J Cancer 2006
191
15

Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.
Akira Tsuchiya, Michiie Sakamoto, Jun Yasuda, Makoto Chuma, Tsutomu Ohta, Misao Ohki, Toshiharu Yasugi, Yuji Taketani, Setsuo Hirohashi. Am J Pathol 2003
228
15

Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary.
Masashi Takano, Tomoko Goto, Masafumi Kato, Naoki Sasaki, Morikazu Miyamoto, Kenichi Furuya. Int J Clin Oncol 2013
9
33

Inhibition of angiogenesis by the antifungal drug itraconazole.
Curtis R Chong, Jing Xu, Jun Lu, Shridhar Bhat, David J Sullivan, Jun O Liu. ACS Chem Biol 2007
137
15

Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
James Kim, Blake T Aftab, Jean Y Tang, Daniel Kim, Alex H Lee, Melika Rezaee, Jynho Kim, Baozhi Chen, Emily M King, Alexandra Borodovsky,[...]. Cancer Cell 2013
246
15

Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.
Charles M Rudin, Julie R Brahmer, Rosalyn A Juergens, Christine L Hann, David S Ettinger, Rosa Sebree, Ruth Smith, Blake T Aftab, Peng Huang, Jun O Liu. J Thorac Oncol 2013
95
15

Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis.
Yoo-Young Lee, Tae-Joong Kim, Min-Ji Kim, Ha-Jeong Kim, Taejong Song, Min Kyu Kim, Chel Hun Choi, Jeong-Won Lee, Duk-Soo Bae, Byoung-Gie Kim. Gynecol Oncol 2011
58
15

Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).
Francesca Esposito, Sabrina Chiara Cecere, Francescapaola Magazzino, Dionyssios Katsaros, Alessandro Ottaiano, Angiolo Gadducci, Carmela Pisano, Simona Scalone, Emanuela Rabaiotti, Vanda Salutari,[...]. Oncology 2014
13
23

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Dimitrios Pectasides, George Fountzilas, Gerassimos Aravantinos, Charalambos Kalofonos, Helen Efstathiou, Dimitrios Farmakis, Dimosthenes Skarlos, Nikolaos Pavlidis, Theofanis Economopoulos, Meletios A Dimopoulos. Gynecol Oncol 2006
106
15

Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
Helen J Mackay, Mark F Brady, Amit M Oza, Alexander Reuss, Eric Pujade-Lauraine, Ann M Swart, Nadeem Siddiqui, Nicoletta Colombo, Michael A Bookman, Jacobus Pfisterer,[...]. Int J Gynecol Cancer 2010
185
15

Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation.
Paul J Hoskins, Nhu Le, Blake Gilks, Anna Tinker, Jennifer Santos, Frances Wong, Kenneth D Swenerton. J Clin Oncol 2012
74
15

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
Kuan-Ting Kuo, Tsui-Lien Mao, Siân Jones, Emanuela Veras, Ayse Ayhan, Tian-Li Wang, Ruth Glas, Dennis Slamon, Victor E Velculescu, Robert J Kuman,[...]. Am J Pathol 2009
302
15


Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.
Ji Yon Agnes Jang, Nozomu Yanaihara, Eric Pujade-Lauraine, Yoshiki Mikami, Katsutoshi Oda, Michael Bookman, Jonathan Ledermann, Muneaki Shimada, Takako Kiyokawa, Byoung Gie Kim,[...]. J Gynecol Oncol 2017
10
30

The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE).
Takayuki Enomoto, Daisuke Aoki, Kana Hattori, Masahisa Jinushi, Junzo Kigawa, Nobuhiro Takeshima, Hitoshi Tsuda, Yoh Watanabe, Kosuke Yoshihara, Toru Sugiyama. Int J Gynecol Cancer 2019
33
15

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Siân Jones, Tian-Li Wang, Ie-Ming Shih, Tsui-Lien Mao, Kentaro Nakayama, Richard Roden, Ruth Glas, Dennis Slamon, Luis A Diaz, Bert Vogelstein,[...]. Science 2010
842
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.